Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification.
Maximilian Y DengFelix HinzSybren L N MaasGünes AnilPhilipp SieversCristina Conde-LopezJonathan LischalkSophie RauhTanja EichkornSebastian RegneryLukas BauerThomas HeldEva MeixnerKristin LangJuliane Hörner-RieberKlaus HerfarthDavid JonesStefan M PfisterChristine JungkAndreas UnterbergWolfgang WickAndreas von DeimlingJürgen DebusFelix SahmLaila KönigPublished in: Neuro-oncology advances (2023)
Integrated risk scoring can identify CNS WHO grade 2 meningioma patients at risk or relapse and dissemination following radiotherapy. Therapeutic management of CNS WHO grade 2 meningiomas and future clinical trials should be adjusted according to the molecular risk-groups, and not rely on conventional CNS WHO grading alone.
Keyphrases